1045 related articles for article (PubMed ID: 22516245)
21. Synchronous hepatocellular carcinoma and cholangiocarcinoma arising in two different dysplastic nodules.
Kwon Y; Lee SK; Kim JS; Ro JY; Yu E
Mod Pathol; 2002 Oct; 15(10):1096-101. PubMed ID: 12379757
[TBL] [Abstract][Full Text] [Related]
22. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
Zhang F; Chen XP; Zhang W; Dong HH; Xiang S; Zhang WG; Zhang BX
Histopathology; 2008 Jan; 52(2):224-32. PubMed ID: 18184271
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma.
Hishinuma M; Ohashi KI; Yamauchi N; Kashima T; Uozaki H; Ota S; Kodama T; Aburatani H; Fukayama M
Histopathology; 2006 Nov; 49(5):479-86. PubMed ID: 17064293
[TBL] [Abstract][Full Text] [Related]
24. Pathology of combined hepatocellular-cholangiocarcinoma.
Yeh MM
J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451
[TBL] [Abstract][Full Text] [Related]
26. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma.
Shetty AS; Fowler KJ; Brunt EM; Agarwal S; Narra VR; Menias CO
Abdom Imaging; 2014 Apr; 39(2):310-22. PubMed ID: 24407728
[TBL] [Abstract][Full Text] [Related]
27. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
28. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Kim KH; Lee SG; Park EH; Hwang S; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
Ann Surg Oncol; 2009 Mar; 16(3):623-9. PubMed ID: 19130133
[TBL] [Abstract][Full Text] [Related]
29. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
30. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
[TBL] [Abstract][Full Text] [Related]
31. Synchronous double cancers of primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a case report and review of the literature.
Wu C; Bai DS; Jiang GQ; Jin SJ
World J Surg Oncol; 2014 Nov; 12():337. PubMed ID: 25385169
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors.
Gonzalez-Roibon N; Katz B; Chaux A; Sharma R; Munari E; Faraj SF; Illei PB; Torbenson M; Netto GJ
Hum Pathol; 2013 Jul; 44(7):1293-9. PubMed ID: 23347651
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
34. Separate histogenesis of combined hepatocellular and cholangiocellular carcinoma in two patients.
Nagafuchi Y; Okamoto K; Shono M; Higure A; Todoroki H; Itoh H; Takeda S; Katumoto F; Toyoshima S
Hepatogastroenterology; 1998; 45(20):523-7. PubMed ID: 9638442
[TBL] [Abstract][Full Text] [Related]
35. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
Tischoff I; Tannapfel A
Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
[TBL] [Abstract][Full Text] [Related]
36. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
37. A resected case of combined hepatocellular carcinoma and cholangiocarcinoma associated with cystic formation.
Utsunomiya T; Saitsu H; Saku M; Takeshita M; Yoshida K; Kajiyama K; Sugimachi K
Hepatogastroenterology; 2000; 47(33):851-4. PubMed ID: 10919046
[TBL] [Abstract][Full Text] [Related]
38. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
[TBL] [Abstract][Full Text] [Related]
39. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
Portolani N; Baiocchi GL; Coniglio A; Piardi T; Grazioli L; Benetti A; Ferrari Bravo A; Giulini SM
Ann Surg Oncol; 2008 Jul; 15(7):1880-90. PubMed ID: 18443881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]